ECSP14010000A - Derivados de quinolina como inhibidores de la enzima pde10a - Google Patents

Derivados de quinolina como inhibidores de la enzima pde10a

Info

Publication number
ECSP14010000A
ECSP14010000A ECIEPI201410000A ECPI201410000A ECSP14010000A EC SP14010000 A ECSP14010000 A EC SP14010000A EC IEPI201410000 A ECIEPI201410000 A EC IEPI201410000A EC PI201410000 A ECPI201410000 A EC PI201410000A EC SP14010000 A ECSP14010000 A EC SP14010000A
Authority
EC
Ecuador
Prior art keywords
inhibitors
quinoline derivatives
compounds
pde10a enzyme
present
Prior art date
Application number
ECIEPI201410000A
Other languages
English (en)
Inventor
Morten Langgard
Jacob Nielsen
Ask Püschl
Jan Kehler
John Paul Kilburn
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14010000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP14010000A publication Critical patent/ECSP14010000A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona derivados de quinolina de fórmula I que son inhibidores de la enzima PDE10A y, como tales, son útiles para tratar trastornos psiquiátricos y neurodegenerativos. En especial, la invención proporciona compuestos que son altamente selectivos para PDE10 respecto de otros subtipos de PDE. La presente invención proporciona además composiciones farmacéuticas que comprenden compuestos de la invención y métodos para tratar trastornos empleando los compuestos de la invención.
ECIEPI201410000A 2011-12-21 2014-07-18 Derivados de quinolina como inhibidores de la enzima pde10a ECSP14010000A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201100990 2011-12-21

Publications (1)

Publication Number Publication Date
ECSP14010000A true ECSP14010000A (es) 2015-12-31

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201410000A ECSP14010000A (es) 2011-12-21 2014-07-18 Derivados de quinolina como inhibidores de la enzima pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (es)
EP (1) EP2794606A1 (es)
JP (1) JP6073918B2 (es)
KR (1) KR20140105574A (es)
CN (1) CN104114554A (es)
AP (1) AP2014007697A0 (es)
AR (1) AR089361A1 (es)
AU (1) AU2012356885B2 (es)
BR (1) BR112014015192A8 (es)
CA (1) CA2859702A1 (es)
CL (1) CL2014001643A1 (es)
CO (1) CO6990727A2 (es)
CR (1) CR20140289A (es)
DO (1) DOP2014000141A (es)
EA (1) EA028824B1 (es)
EC (1) ECSP14010000A (es)
GE (1) GEP201706657B (es)
HK (1) HK1202861A1 (es)
IL (1) IL233226A (es)
MA (1) MA35860B1 (es)
MD (1) MD20140070A2 (es)
MX (1) MX348792B (es)
MY (1) MY165216A (es)
PE (1) PE20141945A1 (es)
PH (1) PH12014501434A1 (es)
RU (1) RU2624440C2 (es)
SG (1) SG11201403339YA (es)
TN (1) TN2014000268A1 (es)
TW (1) TWI570124B (es)
UA (1) UA111871C2 (es)
WO (1) WO2013092974A1 (es)
ZA (1) ZA201404533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
KR20060030483A (ko) 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
CA2530114A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
WO2010145668A1 (en) 2009-06-19 2010-12-23 H. Lundbeck A/S Novel phenylimidazole derivative as pde10a enzyme inhibitor
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
CA2800618C (en) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物

Also Published As

Publication number Publication date
WO2013092974A1 (en) 2013-06-27
NZ626279A (en) 2015-07-31
EA028824B1 (ru) 2018-01-31
AR089361A1 (es) 2014-08-20
US20150376186A1 (en) 2015-12-31
MX2014007409A (es) 2014-08-01
BR112014015192A2 (pt) 2017-06-13
AU2012356885B2 (en) 2016-09-08
AU2012356885A1 (en) 2014-07-10
GEP201706657B (en) 2017-04-25
PH12014501434B1 (en) 2014-09-22
CA2859702A1 (en) 2013-06-27
TW201339156A (zh) 2013-10-01
MA35860B1 (fr) 2014-12-01
KR20140105574A (ko) 2014-09-01
IL233226A (en) 2017-11-30
SG11201403339YA (en) 2014-07-30
RU2624440C2 (ru) 2017-07-04
TN2014000268A1 (en) 2015-09-30
ZA201404533B (en) 2015-12-23
US9801878B2 (en) 2017-10-31
AP2014007697A0 (en) 2014-06-30
PH12014501434A1 (en) 2014-09-22
MD20140070A2 (ro) 2014-12-31
MX348792B (es) 2017-06-29
EP2794606A1 (en) 2014-10-29
IL233226A0 (en) 2014-08-31
CO6990727A2 (es) 2014-07-10
US9216986B1 (en) 2015-12-22
DOP2014000141A (es) 2014-07-31
JP2015502970A (ja) 2015-01-29
JP6073918B2 (ja) 2017-02-01
US20160303120A1 (en) 2016-10-20
RU2014127984A (ru) 2016-02-10
CN104114554A (zh) 2014-10-22
UA111871C2 (uk) 2016-06-24
CL2014001643A1 (es) 2014-11-21
HK1202861A1 (en) 2015-10-09
PE20141945A1 (es) 2014-12-18
CR20140289A (es) 2014-08-18
EA201491152A1 (ru) 2015-01-30
MY165216A (en) 2018-03-09
TWI570124B (zh) 2017-02-11
BR112014015192A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
NI201300073A (es) Compuestos y composiciones como inhibidores de la trk
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CR20150524A (es) Compuestos de heteroarilo y sus usos
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX382607B (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa.
TR201816379T4 (tr) DNA-PK inhibitörleri.
GT201300130A (es) Derivados de imidazol como inhibidores de la enzima pde10a
IN2014DN10576A (es)
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
UA114901C2 (uk) Інгібітори асс та їх застосування
GEAP202413811A (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
UA111198C2 (uk) Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
EA201592238A1 (ru) Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
IN2014CN03062A (es)
CL2019001091A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
IN2014DN10209A (es)
DOP2014000141A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MY168958A (en) Intermediates and processes for preparing compounds